Monoclonal antibodies (mAb) are key therapeutic agents in cancer immunotherapy and exert their effects through Fc receptor-dependent and -independent mechanisms. However, the nanoscale receptor reorganization resulting from mAb binding and its implications for the therapeutic mode of action remain poorly understood. Here, we present a multi-target 3D RESI super-resolution microscopy technique that directly visualizes the structural organization of CD20 receptors and the Type I (e.g., Rituximab) and Type II (e.g., Obinutuzumab) anti-CD20 therapeutic antibodies and quantitatively analyze these interactions at single-protein resolution in situ. We discover that, while Type I mAbs promote higher-order CD20 oligomerization, Type II mAbs induce limited clustering, leading to differences in therapeutic function. Correlating RESI with functional studies for Type II antibodies with different hinge region flexibilities, we show that the oligomeric CD20 arrangement determines the Type I or Type II function. Thus, the nanoscale characterization of CD20-mAb complexes enhances our understanding of the structure-function relationships of therapeutic antibodies and offers insights into the design of next-generation mAb therapies.

Department of Biochemistry Charles University Prague Czech Republic

Department of Biochemistry Ludwig Maximilian University Munich Germany

Faculty of Physics and Center for Nanoscience Ludwig Maximilian University Munich Germany

Max Planck Institute of Biochemistry Planegg Germany

Roche Innovation Center Zurich Roche Pharma and Early Development Schlieren Switzerland

Zobrazit více v PubMed

Pavlasova, G. & Mraz, M. The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy. PubMed PMC

Tsao, L. C., Force, J. & Hartman, Z. C. Mechanisms of therapeutic antitumor monoclonal antibodies. PubMed PMC

Greenall, S. A. et al. Non-agonistic bivalent antibodies that promote c-MET degradation and inhibit tumor growth and others specific for tumor related c-MET. PubMed PMC

Tebbutt, N., Pedersen, M. W. & Johns, T. G. Targeting the ERBB family in cancer: couples therapy. PubMed

Yu, X. et al. Complex interplay between epitope specificity and isotype dictates the biological activity of anti-human CD40 antibodies. PubMed PMC

Jones, S. et al. Targeting of EGFR by a combination of antibodies mediates unconventional EGFR trafficking and degradation. PubMed PMC

Marshall, M. J. E., Stopforth, R. J. & Cragg, M. S. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?. PubMed PMC

Cragg, M. S. & Glennie, M. J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. PubMed

Niederfellner, G. et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. PubMed

Mossner, E. et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. PubMed PMC

Kumar, A., Planchais, C., Fronzes, R., Mouquet, H. & Reyes, N. Binding mechanisms of therapeutic antibodies to human CD20. PubMed

Rouge, L. et al. Structure of CD20 in complex with the therapeutic monoclonal antibody rituximab. PubMed

Klar, T. A., Jakobs, S., Dyba, M., Egner, A. & Hell, S. W. Fluorescence microscopy with diffraction resolution barrier broken by stimulated emission. PubMed PMC

Rust, M. J., Bates, M. & Zhuang, X. Sub-diffraction-limit imaging by stochastic optical reconstruction microscopy (STORM). PubMed PMC

Betzig, E. et al. Imaging intracellular fluorescent proteins at nanometer resolution. PubMed

Reinhardt, S. C. M. et al. Angstrom-resolution fluorescence microscopy. PubMed PMC

Jungmann, R. et al. Single-molecule kinetics and super-resolution microscopy by fluorescence imaging of transient binding on DNA origami. PubMed

Schnitzbauer, J., Strauss, M. T., Schlichthaerle, T., Schueder, F. & Jungmann, R. Super-resolution microscopy with DNA-PAINT. PubMed

Gotzke, H. et al. The ALFA-tag is a highly versatile tool for nanobody-based bioscience applications. PubMed PMC

Ester, M., Kriegel, H.-P., Sander, J. & Xu, X. in

Zhang, X. et al. 3D structural fluctuation of igg1 antibody revealed by individual particle electron tomography. PubMed PMC

Shaw, A. et al. Binding to nanopatterned antigens is dominated by the spatial tolerance of antibodies. PubMed PMC

Diebolder, C. A. et al. Complement is activated by IgG hexamers assembled at the cell surface. PubMed PMC

Bacac, M. et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. PubMed

Teeling, J. L. et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. PubMed

Pawluczkowycz, A. W. et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. PubMed

Bondza, S. et al. Complement-dependent activity of CD20-specific IgG correlates with bivalent antigen binding and C1q binding strength. PubMed PMC

Franke, A., Niederfellner, G. J., Klein, C. & Burtscher, H. Antibodies against CD20 or B-cell receptor induce similar transcription patterns in human lymphoma cell lines. PubMed PMC

Edelmann, J. et al. Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. PubMed PMC

Nguyen, T. T. et al. Efficacy and safety of add-on anti-CD20 monoclonal antibody to Bruton tyrosine kinase inhibitor treatment for chronic lymphocytic leukemia: a meta-analysis. PubMed PMC

Strasser, J. et al. Unraveling the macromolecular pathways of IgG oligomerization and complement activation on antigenic surfaces. PubMed

Abendstein, L. et al. DNA nanostructure-templated antibody complexes provide insights into the geometric requirements of human complement cascade activation. PubMed PMC

Mortensen, S. A. et al. Structure and activation of C1, the complex initiating the classical pathway of the complement cascade. PubMed PMC

Reid, K. B. M. Complement component C1q: historical perspective of a functionally versatile, and structurally unusual, serum protein. PubMed PMC

Gwosch, K. C. et al. MINFLUX nanoscopy delivers 3D multicolor nanometer resolution in cells. PubMed

Balzarotti, F. et al. Nanometer resolution imaging and tracking of fluorescent molecules with minimal photon fluxes. PubMed

Masullo, L. A. et al. An alternative to MINFLUX that enables nanometer resolution in a confocal microscope. PubMed PMC

Sahl, S. J. et al. Direct optical measurement of intramolecular distances with angstrom precision. PubMed

Weber, M. et al. MINSTED fluorescence localization and nanoscopy. PubMed PMC

Ostersehlt, L. M. et al. DNA-PAINT MINFLUX nanoscopy. PubMed PMC

Li, B. et al. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma. PubMed

Huang, B., Wang, W., Bates, M. & Zhuang, X. Three-dimensional super-resolution imaging by stochastic optical reconstruction microscopy. PubMed PMC

Edelstein, A. D. et al. Advanced methods of microscope control using muManager software. PubMed PMC

Hellmeier, J. et al. Quantification of absolute labeling efficiency at the single-protein level. PubMed PMC

Masullo, L. A. et al. Spatial and stoichiometric in situ analysis of biomolecular oligomerization at single-protein resolution. PubMed PMC